We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
- Authors
Nishimura, Tadashi; Fujimoto, Hajime; Okano, Tomohito; Naito, Masahiro; Tsuji, Chikashi; Iwanaka, Soichi; Sakakura, Yasumasa; Yasuma, Taro; D'Alessandro-Gabazza, Corina N.; Oomoto, Yasuhiro; Gabazza, Esteban C.; Kobayashi, Tetsu; Ibata, Hidenori
- Abstract
Simple Summary: Previous studies have shown that the use of chemotherapy in combination with immune checkpoint inhibitors as a first-line treatment in patients with non-small cell lung cancer improved overall survival and progression-free survival. However, the efficacy of cytotoxic agents as a second-line or later-line therapy in non-small cell lung cancer patients previously treated with immune checkpoint inhibitors in the real-world clinical practice is still controversial. In the present study, we retrospectively evaluated patients with non-small cell lung cancer to clarify whether the previous treatment with immune checkpoint inhibitors impacts the efficacy of docetaxel or the combined therapy of docetaxel plus ramucirumab. The results of this study using real-world data show that the addition of ramucirumab to docetaxel is superior to docetaxel monotherapy for improving time-to-treatment failure and overall survival, irrespective of previous treatment with immune checkpoint inhibitors. Reports on the efficacy of second-line treatment with cytotoxic agents after treatment with immune checkpoint inhibitors are limited. Here, we retrospectively evaluated patients in the real-world clinical practice treated with docetaxel or docetaxel plus ramucirumab. Ninety-three patients treated with docetaxel or docetaxel plus ramucirumab as a second- or later-line therapy were included. The patients were categorized into the following four treatment groups: docetaxel group (n = 50), docetaxel/ramucirumab group (n = 43) and pretreated (n = 45) and untreated (n = 48) with immune checkpoint inhibitor groups. The docetaxel/ramucirumab group showed an overall response rate of 57.1% in patients pretreated with immune checkpoint inhibitors and 20% in untreated patients. The docetaxel group showed an overall response rate of 15.4% in patients pretreated with immune checkpoint inhibitors and 5.0% in untreated patients. The median time-to-treatment failure and the median survival time were longer in the docetaxel/ramucirumab group than in the docetaxel group in both immune checkpoint inhibitor-pretreated and -untreated groups. There was no difference in time-to-treatment failure and overall survival between immune checkpoint inhibitor-pretreated and -untreated groups in each docetaxel and docetaxel/ramucirumab treatment group. In conclusion, our real-world data show that the addition of ramucirumab to docetaxel was superior to docetaxel monotherapy for improving time-to-treatment failure and overall survival, irrespective of previous treatment with immune checkpoint inhibitors.
- Subjects
THERAPEUTIC use of monoclonal antibodies; DRUG efficacy; IMMUNE checkpoint inhibitors; COMBINATION drug therapy; RETROSPECTIVE studies; ANTINEOPLASTIC agents; TREATMENT effectiveness; TREATMENT failure; DOCETAXEL; DESCRIPTIVE statistics; SURVIVAL analysis (Biometry); MEDICAL practice; TUMORS
- Publication
Cancers, 2022, Vol 14, Issue 12, p2970
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers14122970